Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment Mounjaro did not demonstrate superiority over Trulicity, its older GLP-1 ...
Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results